Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Analysts

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six ratings firms that are covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $16.75.

Separately, William Blair reissued an "outperform" rating on shares of Alto Neuroscience in a report on Friday.

Alto Neuroscience Price Performance

ANRO stock traded down $0.09 during trading on Friday, reaching $2.56. 218,997 shares of the company were exchanged, compared to its average volume of 360,312. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10. The stock's 50 day moving average price is $3.56 and its 200 day moving average price is $5.90. Alto Neuroscience has a 52-week low of $2.58 and a 52-week high of $18.35. The company has a market cap of $69.04 million and a P/E ratio of -1.01.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.56) earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.09. As a group, analysts predict that Alto Neuroscience will post -2.54 earnings per share for the current fiscal year.

Remove Ads

Institutional Investors Weigh In On Alto Neuroscience

A number of large investors have recently bought and sold shares of ANRO. Wellington Management Group LLP increased its position in Alto Neuroscience by 27.2% during the 4th quarter. Wellington Management Group LLP now owns 77,146 shares of the company's stock worth $326,000 after purchasing an additional 16,510 shares in the last quarter. AWM Investment Company Inc. boosted its position in Alto Neuroscience by 22.9% during the fourth quarter. AWM Investment Company Inc. now owns 687,831 shares of the company's stock worth $2,910,000 after acquiring an additional 128,100 shares during the last quarter. Woodline Partners LP grew its stake in Alto Neuroscience by 397.6% in the 4th quarter. Woodline Partners LP now owns 621,976 shares of the company's stock worth $2,631,000 after acquiring an additional 496,976 shares during the period. Vestal Point Capital LP raised its holdings in Alto Neuroscience by 40.8% in the 4th quarter. Vestal Point Capital LP now owns 915,000 shares of the company's stock valued at $3,870,000 after acquiring an additional 265,000 shares during the last quarter. Finally, Two Sigma Investments LP grew its position in shares of Alto Neuroscience by 137.2% in the fourth quarter. Two Sigma Investments LP now owns 30,700 shares of the company's stock valued at $130,000 after purchasing an additional 17,760 shares during the period.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.